Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

0.9480 -0.0070 (-0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 167,261
Open 0.9900
Bid (Size) 0.9250 (1)
Ask (Size) 0.9900 (6)
Prev. Close 0.9550
Today's Range 0.9300 - 1.000
52wk Range 0.5100 - 5.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Via ACCESS Newswire
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
Via ACCESS Newswire

Performance

YTD
-17.6%
-17.6%
1 Month
+4.2%
+4.2%
3 Month
-17.6%
-17.6%
6 Month
-21.0%
-21.0%
1 Year
-11.4%
-11.4%

More News

Read More
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug
Via Benzinga
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
Via ACCESS Newswire
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Via ACCESSWIRE
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Via ACCESSWIRE
Peering Into Mira Pharmaceuticals's Recent Short Interest
Via Benzinga
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate
Via Benzinga
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Via ACCESS Newswire
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain
Via Benzinga
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Via ACCESSWIRE
EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
Via Benzinga
Exposures Product Safety
EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain
Via Benzinga
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Via ACCESSWIRE
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
Via News Direct
Topics Cannabis
Exposures Cannabis
Why Mira Shares Are Trading Higher Today
Via Benzinga
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Via ACCESSWIRE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
Via News Direct
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
Via ACCESSWIRE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Via ACCESSWIRE
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
Via News Direct

Frequently Asked Questions

Is MIRA Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, MIRA Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does MIRA Pharmaceuticals, Inc. - Common Stock trade on?
MIRA Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock is MIRA on the Nasdaq Stock Market
What is the current price of MIRA Pharmaceuticals, Inc. - Common Stock?
The current price of MIRA Pharmaceuticals, Inc. - Common Stock is 0.9480
When was MIRA Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of MIRA Pharmaceuticals, Inc. - Common Stock was at 04/02/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.